Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes

Cancer Research

Volumn 56, Issue 22, 1996, Pages 5211-5216

  Koo, Han Mo ^a   Monks, Anne ^b   Mikheev, Andrei ^c,f   Rubinstein, Larry V ^d   Gray Goodrich, Marcia ^b   McWilliams, Mary Jane ^a   Alvord, W Gregory ^a   Oie, Herbert K ^d   Gazdar, Adi F ^e   Paull, Kenneth D ^d   Zarbl, Helmut ^c,f   Vande Woude, George F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FIACITABINE; GYRASE INHIBITOR;

ALLELE; APOPTOSIS; ARTICLE; CANCER GROWTH; COLON CARCINOMA; DNA REPAIR; DRUG SENSITIVITY; ENZYME INHIBITION; GENE ACTIVATION; GENE MUTATION; GENETIC REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; ONCOGENE RAS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; COLONIC NEOPLASMS; CYTARABINE; DAUNORUBICIN; DEOXYCYTIDINE; DNA MUTATIONAL ANALYSIS; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; LUNG NEOPLASMS; SOFTWARE; TUMOR CELLS, CULTURED;

EID: 10544253077     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Nowell, P. C. The clonal evolution of tumor cell populations. Science (Washington DC), 194: 23-28, 1976.
2. Nicolson, G. L. Tumor cell instability, diversification, and progression to the metastatic phenotype from oncogene to oncofetal expression. Cancer Res., 47: 1473-1487, 1987.
3. Modrich, P. Mismatch repair, genetic stability, and cancer Science (Washington DC), 266: 1959-1960, 1994.
4. MacPhee, D. G. Mismatch repair, somatic mutations, and the origins of cancer. Cancer Res., 55: 5489-5492, 1995.
5. Kaufmann, W. K. Cell cycle checkpoints and DNA repair preserve the stability of the human genome. Cancer Metastasis Rev., 14: 31-41, 1995.
6. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells Cell, 71: 543-546, 1992.
7. Weinert, T., and Lydall, D. Cell cycle checkpoints, genetic instability and cancer Cancer Biol., 4: 129-140, 1993.
8. Vande Woude, G. F. Schulz, N., Zhou, R., Paules, R. S., Daar, I., Yew, N., and Oskarsson, M. Cell cycle regulation, oncogenes, and antineoplastic drugs In General Motors Cancer Research Foundation: 1990 Views of Cancer Research, pp 128-143. Philadelphia, PA: J. B. Lippincott Co., 1990.
9. Murakami, M. S., Strobel, M. C., and Vande Woude, G. F. Cell cycle regulation, oncogenes, and antineoplastic drugs. In: P. M. Howley, M. A. Israel, and L. A. Liotta (eds.), The Molecular Basis of Cancer, pp. 3-17. Philadelphia: W. B. Saunders, Co., 1994.
10. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer Science (Washington DC), 266: 1821-1828, 1994.
11. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 267: 1456-1462, 1995.
12. Kastan, M. B., Canman, C. E., and Leonard, C. J. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev., 14: 3-15, 1995.
13. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 260: 807-810, 1994.
14. Schaefer, D. I., Livanos, E. M., White, A. E., and Tlsty, T. D. Multiple mechanisms of N-(phosphonoacetyl)-L-aspartate drug resistance in SV40-infected precrisis human fibroblasts. Cancer Res., 53: 4946-4951, 1993.
15. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents Cancer Res., 54: 5824-5830, 1994.
16. Morgan, W. F., and Murnane, J. P. A role for genomic instability in cellular radioresistance? Cancer Metastasis Rev., 14: 49-58, 1995.
17. Grever, M. R., Schepartz, S. A., and Chabner, B. A. The National Cancer Institute. Cancer Drug and Discovery and Development Program. Sem. Oncol., 19: 622-638, 1992.
18. Bos, J. L. ras oncogenes in human cancer: a review Cancer Res., 49: 4682-4689, 1989.
19. Barbacid, M. ras oncogenes: their role in neoplasia Eur. J. Clin. Invest., 20: 225-235, 1990.
20. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J., and Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human rumor cell lines J. Natl. Cancer. Inst., 83: 757-766, 1991.
21. Paull, K. D., Hamel, E., and Malspeis, L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: W. O. Foye (ed.) Cancer Chemotherapeutic Agents, pp 9-45. Washington, DC: American Chemical Society, 1995.
22. Gupta, M., Abdel-Megeed, M., Hoki, Y., Kohlhagen, G., Paull, K., and Pommier, Y. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517. Mol. Pharmacol., 48: 658-665, 1995.
23. Solary, E., Leteurtre, F., Paull, K., Scudiero, D., Hamel, E., and Pommier, Y. Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem. Pharmacol., 45: 2449-2456, 1993.
24. Leteurtre, F., Sackett, D. L., Madalengoitia, J., Kohlhagen, G., MacDonald, T., Hamel, E., Paull, K. D., and Pommier, Y. Azatoxin derivatives with potent and selective action on topoisomerase II. Biochem. Pharmacol., 49: 1283-1290, 1995.
25. Leteurtre, F., Kohlhagen, G., Paull, K. D., and Pommier, Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J. Natl. Cancer Inst., 86: 1239-1244, 1994.
26. Cleaveland, E. S., Monks, A., Vaigro-Wolfe, A., Zaharevitz, D. W., Paull, K., Ardalan, K., Cooney, D. A., and Ford, H. J. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the COMPARE program. Biochem. Pharmacol., 49: 947-954, 1995.
27. Bai, R., Paull, K. D., Herald, C. L., Malspeis, L., Pettit, G. R., and Hamel, E. Halichondrin B and homohalichondrin B. marine natural products binding in the Vinca domain of tubulin. J. Biol. Chem., 266: 15882-15889, 1991.
28. Paull, K. D., Lin, C. M., Malspeis, L., and Hamel, E. Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res., 52: 3892-3900, 1992.
29. Kuo, S-C., Lee, H-Z., Juang, J-P., Lin, Y-T., Wu, T-S., Chang, J-J., Lednicer, D., Paull, K. D., Lin, C. M., Hamel, E., and Lee, K-H. Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4′-substituted phenyl)-4-quinolones, and related compounds: identification as antimitotic agents interacting with tubulin. J. Med. Chem., 36: 1146-1156, 1993.
30. Alvarez, M., Paull, K., Monks, A., Hose, C., Lee, J-S., Weinstein, J., Grever, M., Bates, S., and Fojo, T. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J. Clin. Invest., 95: 2205-2214, 1995.
31. Lee, J-S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., and Bates, S. E. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen. Mol. Pharmacol., 46: 627-638, 1994.
32. Mitsudomi, T., Viallet, J., Mulshine, J. L., Linnoila, R. I., Minna, J. D., and Gazdar, A. F. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines Oncogene, 6: 1353-1362, 1991.
33. Mikheev, A., Cha, R. S., and Zarbl, H. Detection of point mutations in Ras in tumor cell lines by denaturant gradient gel electrophoresis Methods Enzymol., 255: 442-451, 1995.
34. Chabner, B. A. Anticancer Drugs In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles & Practice of Oncology. Ed 4, pp. 325-417. Philadelphia: J. B. Lippincott Co., 1993.
35. Hoshi, A., Kanzawa, F., Kubetani, K., Saneyoshi, M., and Arai, Y. 2,2′-O-Cyclocytidine: antitumor cytidine analog resistant to cytidine deaminase. Gann, 62: 145-146, 1971.
36. Novotny, L., Farhall, H., Janku, I., and Beranek, J. Comparative study of cyclocytidine and arabinosylcytosine disposition in rats. Neoplasma, 35: 707-714, 1988.
37. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1988.
38. van Haperen, V. W. T. R., and Peters, G. J. New targets for pyrimidine antimetabolites for the treatment of solid tumours. Pharmacy World Sci., 16: 104-112, 1994.
39. Grunewald, R., Kantarjian, H., Du, M., Faucher, K., Tarassoff, P., and Plunkett, W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J. Clin. Oncol. 10: 406-413, 1992.
40. Abbruzzese, J. L., Grunewald, R., Weeks, E. A., Gravel, D., Adams, T., Nowak, B., Minetshi, S., Tarassoff, P., Satterlee, W., Raber, M. N., and Plunkett, W. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol., 9: 491-498, 1991.
41. Lund, B., Kristjansen, P. E. G., and Hansen, H. H. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treatment Rev., 19: 45-55, 1993.
42. Casper, E. S., Green, M. R., Kelsen, D. P., Heelen, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B., and Tarassoff, P. G. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs, 12: 29-34, 1994.
43. Carmichael, J., Fink, U., Russell, R. C. G., Spittle, M. F., Harris, A. L., Spiessi, G., and Blatter, J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer. 73: 101-105, 1996.
44. Shepherd, F. A., Gatzemeier, U., Gotfried, M., Weynants, P., Cottier, B., Groen, H., Rosso, R., Mattson, K., Comes-Funes, H., Tonato, M., Hatty, S., and Voi, M. An extended phase II study or gemcitabine in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 12: 330, 1993.
45. Abratt, R. P., Bezwoda, W. R., Falkson, G., Goedhals, L., Hacking, D., and Rugg, T. A. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 12: 1535-1540, 1994.
46. Anderson, H., Lund, B., Bach, F., Thatcher, N., Walling, J., and Hansen, H. H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol., 19: 1821-1826, 1994.
47. Fuchs, E-F., Horton, D., Weckerle, W., and Winter-Mihaly, E. Synthesis and antitumor activity of sugar-ring hydroxyl analogues of daunorubicin J. Med. Chem., 22: 406-411, 1979.
48. Jasztold-Howorko, R., Landras, C., Pierre, A., Atassi, G., Guilbaud, N., Kraus-Benhier, L., Leonce, S., Rolland, Y., Prost, J-F., and Bisagni, E. Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5,6-dimethyl-6H-pyndo[4,3-b]carbazole-1-N-[(dialkylamino)alkyl]carboxamides, a new promising series of antitumor olivacine derivatives. J. Med. Chem., 37: 2445-2452, 1994.
49. Keating, M. J., Estey, E., and Kantarjian, H. Acute leukemia In V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles & Practice of Oncology, Ed. 4, pp. 1938-1964 Philadelphia: J. B. Lippincott Co., 1993.
50. Rohatiner, A. Z. S., and Lister, T. A. The treatment of acute myelogenous leukemia. In: E. S. Henderson and T. A. Lister (eds.), Leukemia, Ed. 5, pp. 485-514. Philadelphia: W. B. Saunders Co., 1990.
51. Neubauer, A., Dodge, R. K., George, S. L., Davey, F. R., Silver, R. T., Schiffer, C. A., Mayer, R. J., Ball, E. D., Wurster-Hill, D., Bloomfield, C. D., and Liu, E. T. Prognostic importance in the ras proto-oncogenes in de nova acute myeloid leukemia. Blood. 83: 1603-1611, 1994.
52. Liu, E. T. The role of ras gene mutations in myeloproliferative disorders. Clinics Lab. Med., 10: 797-807, 1990.
53. Liu, E. T., Dodge, R., Meyer, A., Zhang, X. X., Schiffer, C., Mayer, R., and Bloomfield, C. D. De novo acute myeloid leukemias harboring ras mutations exhibit preferential sensitivity to dose intensive cytarabine as consolidation therapy. Blood. 86: (Suppl. 1): 2380, 1995.
54. ODAC okays gemcitabine for pancreatic cancer. Cancer Lett., 21: 6-7, 1995.